Bladder pain caused by cystitis can be severe and difficult to control because inflammation sensitizes the nerves that carry pain signals from the urinary tract. In this preclinical study, combined activation of peripheral cannabinoid CB1 and CB2 receptors completely abolished cystitis-induced bladder hyperalgesia. The findings suggest that targeting both cannabinoid receptors outside the central nervous system may provide powerful pain relief while potentially avoiding some of the unwanted effects associated with centrally acting cannabinoids. The study highlights peripheral CB1/CB2 signaling as a promising therapeutic target for painful bladder disorders.

“Cannabinoid agonists may ameliorate bladder pain associated with interstitial cystitis/bladder pain syndrome.

Visceromotor responses (VMRs) to bladder distension were recorded in urethane-anesthetised control and protamine/zymosan-treated guinea pigs. The peripherally restricted preferential CB1 receptor agonist PrNMI and the selective CB2 receptor agonist 4Q3C each reduced cystitis-induced enhancement of VMRs at high intravesical pressures.

Co-activation of CB1 and CB2 receptors abolished cystitis-induced bladder hyperalgesia.

These findings indicate that simultaneous targeting of peripheral CB1 and CB2 receptors may provide clinically meaningful benefits for the treatment of bladder pain associated with cystitis.”

https://pubmed.ncbi.nlm.nih.gov/42247877

“Combined activation of peripheral CB1 and CB2 receptors using peripherally restricted agonists effectively reverses bladder hyperalgesia in a preclinical model of IC/BPS.

These findings provide strong support for the development of peripherally acting combination therapies targeting both cannabinoid receptors as a strategy to treat bladder pain and associated symptoms in IC/BPS, while minimising central cannabinoid-related side effects.”

https://www.autonomicneuroscience.com/article/S1566-0702(26)00066-4/fulltext